ALBACORE-CAPITAL-GROUP
European credit specialist AlbaCore Capital Group (“AlbaCore”), today announces three senior hires to reinforce its Operations, Business Development and Investor Relations teams.
As part of the growth of the AlbaCore platform, investing across the European credit spectrum with $8.5bn1 AUM, AlbaCore has bolstered its senior executive group. Jenny Fung is appointed as Managing Director of Investor Relations in New York to further expand global investor relationships and our commitment to the region. Tara Mulholland joins as Head of Business Transformation and Micaela Kelley as Deputy Chief Operating Officer to support Matthew Courey, Chief Operating Officer and Founding Partner.
Jenny brings a wealth of financial services experience with 25 years in the industry. She joins from Taconic Capital, a global investment firm, where she was Director of Marketing and Investor Relations for 13 years, and prior to that at Bank of America, AIG and CSFB.
Tara will oversee an operational change programme across the firm, joining with 19 years’ experience from Cheyne Capital where she was a Partner and served as Head of Business Transformation, Chief Administrative Officer and Head of Operations.
Micaela joins with over 11 years of experience as a Chief Operating Officer with alternative funds. She joins from JNE Partners where she served as Partner and Chief Operating Officer following the spin-out from MSD Partners, and previously as Partner and Chief Operating Officer of Observatory Capital Management. Micaela has 17 years prior experience in prime brokerage and credit risk management at Goldman Sachs and Morgan Stanley.
Matthew Courey, Founding Partner and Chief Operating Officer at AlbaCore Capital Group, commented: “We are excited to have Jenny, Tara and Micaela join the AlbaCore team. Their unique backgrounds and depth of experience will continue to drive our business and position our team optimally for the many opportunities ahead”.
David Allen, Managing Partner and Chief Investment Officer at AlbaCore Capital Group added: “I am delighted that such high calibre executives have chosen to join the firm. We are proud of the talented team we have built at AlbaCore with 20 nationalities and a diverse set of backgrounds and experiences. Tara, Micaela and Jenny will further strengthen our ability to deliver for our investors across the credit spectrum”.
Since the start of 2021, AlbaCore has appointed 15 new professionals across its Investment, Investor Relations, Legal and Compliance, Finance, Operations, Systems and Risk teams, including hires from Albourne, Canyon Capital Advisors, CVC Capital Partners, The Carlyle Group, Citi, EQT Partners and Marathon Asset Management Capital taking the total team size to 53 individuals.
- ENDS –
About AlbaCore Capital Group
AlbaCore Capital Group is one of Europe’s leading specialist credit investors focusing on public and private corporate credit markets. The senior investment team have been investing with this hybrid strategy for over a decade2 . Founded in 2016, AlbaCore has invested over $17bn3 for global pension funds, sovereign wealth funds, consultants, insurance companies, family offices and endowments.
AlbaCore is focused on consistently outperforming the market in the long term while protecting investor capital. The credit selection process is based on fundamental research with a focus on capital preservation, ESG factors and risk-adjusted returns.
Headquartered in London with offices in New York and Dublin, AlbaCore has a partnership approach with values at the center of the AlbaCore community.
1 AUM as at 31 July 2021
2 Including period prior to AlbaCore at the Canada Pension Plan Investment Board (“CPPIB”).
3 Invested capital is the sum of all 'buy' trades for all AlbaCore mandates since inception to 31 July 2021, and includes recycled capital and co-investment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210920005412/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Positive Phase 3 Results Support ZIIHERA® as HER2-Targeted Therapy-of-Choice and Combination with TEVIMBRA® and Chemotherapy as New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma17.11.2025 12:00:00 CET | Press release
ZIIHERAplus TEVIMBRA and chemotherapy demonstrated clinically meaningful and statistically significant improvements in PFS and OS versus trastuzumab and chemotherapyZIIHERA plus chemotherapy showed a clinically meaningful and statistically significant improvement in PFS versus trastuzumab and chemotherapy, and a clinically meaningful effect with a strong trend toward statistical significance for OS at the first interim analysisFirst Phase 3 trial in 15 years to demonstrate a clinical benefit in this patient population with a novel HER2-targeted therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive top-line results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with or without PD-1 inhibitor TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcin
BoConcept, Lego, Lurpak, and Pandora are among the Honoured Winners of the 2025-2026 World Branding Awards in Osaka17.11.2025 11:48:00 CET | Press release
The 20th World Branding Awards celebrated the success and achievements of leading brands across National, Regional, and Global categories. In the 2025–2026 edition, over 1,092 brands from 66 countries were nominated as “Brand of the Year”. From this distinguished selection, fewer than 100 brands emerged as winners, representing the highest standards of excellence across the three tiers of recognition. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. Over 80 international guests joined the celebration, hosted by Allie Sakakibara and enriched by a keynote from Miho Noguchi on immersive brand experiences. Honoured as Global winners in branding across diverse industries were Cadbury (USA), IKEA (Sweden), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). Winners from Denmark include BoConcept, Lego, Lurpak, and Pandora.Other National tier winners incl
Global Winners of the 2025–2026 World Branding Awards Announced at First-Ever Japan Ceremony17.11.2025 11:43:00 CET | Press release
Now in its 20th edition, the World Branding Awards continues to spotlight the world’s most impactful and trusted brands. This year, over 1,092 brands from 66 countries were nominated as “Brand of the Year”, with less than 100 declared Winners across Global, Regional, and National tiers. The World Branding Awards Ceremony stepped outside London for the first time, bringing its global presence to the Osaka City Museum of Fine Arts. The 2025–2026 edition welcomed over 80 international guests and was presented by the acclaimed Allie Sakakibara. The evening was further elevated by a keynote presentation from Miho Noguchi, who shared insights on building emotional resonance through immersive brand experiences. Global Tier winners celebrated their outstanding branding excellence across various industries, including IKEA (Sweden), Lurpak (Denmark), Marriott International (United Kingdom), Nike (USA), Sennheiser (Germany), and Yakult (Japan). These brands consistently demonstrated strength, inf
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US17.11.2025 11:30:00 CET | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.1 POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality and potentially more affordable biologic therapies for patients with certain HER2-positive breast cancers.2 "Expanding access to treatments for diseases that disproportionately impact women, including breast cancer, the most common cancer among women in the US excluding skin cancer, is at the core of our mission,” said Jon Martin, US Commercial Lead, Biosimilars and Established Brands at Organon.3 “Not only is POHERDY the first approved biosimilar to PERJETA in the US, but its approval also builds
WEX® Unlocks Access to 20,000+ Tesla Superchargers Across Europe17.11.2025 11:15:00 CET | Press release
EV drivers of any car brand using the EV Driver by WEX app can now charge at one of Europe’s largest and most reliable charging networks, benefitting from low-cost fast charging across 1,500+ locations. WEX® (NYSE: WEX), the global commerce platform that simplifies the business of running a business, today announced integration with the Tesla Supercharger network, adding over 20,000 fast-charging points across 1,500+ locations to its platform. The move significantly expands charging options for WEX’s customers, particularly in areas where high-power charging has been limited or expensive. By bringing Tesla Superchargers into their ecosystem, WEX gives drivers access to competitively priced fast charging with speeds up to 250 kW, increasing availability of high-power charging stations by 10%. WEX customers already use the EV Driver by WEX app to charge at over 1 million charging points throughout Europe. Now, they can access Tesla Superchargers with the same seamless experience: compari
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom